SG11201806380SA - Endoplasmic reticulum stress as a predictive tool in cancer therapy and a combination therapy for the treatment of cancer - Google Patents

Endoplasmic reticulum stress as a predictive tool in cancer therapy and a combination therapy for the treatment of cancer

Info

Publication number
SG11201806380SA
SG11201806380SA SG11201806380SA SG11201806380SA SG11201806380SA SG 11201806380S A SG11201806380S A SG 11201806380SA SG 11201806380S A SG11201806380S A SG 11201806380SA SG 11201806380S A SG11201806380S A SG 11201806380SA SG 11201806380S A SG11201806380S A SG 11201806380SA
Authority
SG
Singapore
Prior art keywords
cancer
international
therapy
treatment
jerusalem
Prior art date
Application number
SG11201806380SA
Inventor
Yoram Devary
Uziel Sandler
Original Assignee
Immune System Key Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune System Key Ltd filed Critical Immune System Key Ltd
Publication of SG11201806380SA publication Critical patent/SG11201806380SA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 10 August 2017 (10.08.2017) WIPO I PCT (10) International Publication Number WO 2017/134668 Al 11111111111111 0 111011111111111 010 11111 01110111 011111111 11111E11110 11111111111 0111111 (51) International Patent Classification: G01N 33/53 (2006.01) A61K 38/10 (2006.01) C12Q 1/68 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/IL2017/050129 (22) International Filing Date: 2 February 2017 (02.02.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/291,190 4 February 2016 (04.02.2016) US (71) Applicant: IMMUNE SYSTEM KEY LTD. [IL/IL]; Rozenblat Street 318/7, 9746024 Jerusalem (IL). (72) Inventors: DEVARY, Yoram; Rozenblat Street 318/7, Ramot G, 9746024 Jerusalem (IL). SANDLER, Uziel; Neve Yaakov Street 508/24, 97350 Jerusalem (IL). (74) Agent: GALL, Arad Haase; Reinhold Cohn And Partners, P.O.B. 13239, 61131 Tel-Aviv (IL). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) W O 20 17 / 13 4668 Al (54) Title: ENDOPLASMIC RETICULUM STRESS AS A PREDICTIVE TOOL IN CANCER THERAPY AND A COMBINA- TION THERAPY FOR THE TREATMENT OF CANCER (57) : The present invention provides methods, agents and kits for use in assessing the effect of treatment on cancer pa - tients. In addition the present invention relates to a combination therapy for reducing the administered standard of care doses of anti- cancer agents in treated cancer patients.
SG11201806380SA 2016-02-04 2017-02-02 Endoplasmic reticulum stress as a predictive tool in cancer therapy and a combination therapy for the treatment of cancer SG11201806380SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662291190P 2016-02-04 2016-02-04
PCT/IL2017/050129 WO2017134668A1 (en) 2016-02-04 2017-02-02 Endoplasmic reticulum stress as a predictive tool in cancer therapy and a combination therapy for the treatment of cancer

Publications (1)

Publication Number Publication Date
SG11201806380SA true SG11201806380SA (en) 2018-08-30

Family

ID=59500674

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202007237UA SG10202007237UA (en) 2016-02-04 2017-02-02 Endoplasmic reticulum stress as a predictive tool in cancer therapy and a combination therapy for the treatment of cancer
SG11201806380SA SG11201806380SA (en) 2016-02-04 2017-02-02 Endoplasmic reticulum stress as a predictive tool in cancer therapy and a combination therapy for the treatment of cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202007237UA SG10202007237UA (en) 2016-02-04 2017-02-02 Endoplasmic reticulum stress as a predictive tool in cancer therapy and a combination therapy for the treatment of cancer

Country Status (12)

Country Link
US (2) US10933117B2 (en)
EP (1) EP3411711B1 (en)
JP (1) JP2019512669A (en)
CN (2) CN116688096A (en)
AU (1) AU2017214850B2 (en)
CA (1) CA3013552A1 (en)
DK (1) DK3411711T3 (en)
ES (1) ES2927240T3 (en)
IL (1) IL260946B (en)
RU (1) RU2018130764A (en)
SG (2) SG10202007237UA (en)
WO (1) WO2017134668A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023199313A1 (en) * 2022-04-11 2023-10-19 Immune System Key Ltd. Bcl2 inhibitor and peptide combination therapy for treating proliferative diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002077176A2 (en) 2001-03-22 2002-10-03 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Aberrantly expressed proteins in laser capture microdissected tumors
HUP0303749A3 (en) 2001-04-03 2005-09-28 Merck Patent Gmbh Renal cell carcinoma tumor markers
KR101310511B1 (en) * 2004-10-25 2013-09-25 임뮨 시스템 키 리미티드 A thymus-specific protein
WO2007091240A2 (en) 2006-02-06 2007-08-16 Immune System Key Ltd. Treatment of immunological diseases
WO2007122622A1 (en) 2006-04-24 2007-11-01 Immune System Key Ltd. Method of treatment of a disease
WO2008042508A1 (en) 2006-10-03 2008-04-10 University Of Southern California Grp78 as a predictor of responsiveness to therapeutic agents
US20100204097A1 (en) 2006-12-18 2010-08-12 Immune System Key Ltd. Therapeutic methods using a thymus peptide
TW200931019A (en) 2008-01-11 2009-07-16 Univ Chang Gung Marking molecule capable of forecasting the degree of malignancy of head-and-neck cancer and method thereof
US9580513B2 (en) * 2008-08-08 2017-02-28 Agency For Science, Technology And Research (A*Star) VHZ for diagnosis and treatment of cancers
CN102375061B (en) * 2011-09-20 2014-07-30 国家人口计生委科学技术研究所 ELISA (Enzyme Linked Immunosorbent Assay) kit for detecting prostate cancer
CA2931023C (en) * 2013-12-05 2023-12-19 Immune System Key Ltd. Pharmaceutical compositions of isolated peptides for the treatment of metastatic cancer

Also Published As

Publication number Publication date
AU2017214850B2 (en) 2024-01-04
US20210154262A1 (en) 2021-05-27
IL260946B (en) 2020-11-30
US11813305B2 (en) 2023-11-14
US10933117B2 (en) 2021-03-02
CN109069585A (en) 2018-12-21
DK3411711T3 (en) 2022-10-10
EP3411711A4 (en) 2020-02-12
US20180333452A1 (en) 2018-11-22
EP3411711A1 (en) 2018-12-12
AU2017214850A1 (en) 2018-09-13
JP2019512669A (en) 2019-05-16
ES2927240T3 (en) 2022-11-03
KR20180104083A (en) 2018-09-19
SG10202007237UA (en) 2020-09-29
EP3411711B1 (en) 2022-08-03
WO2017134668A1 (en) 2017-08-10
CA3013552A1 (en) 2017-08-10
CN116688096A (en) 2023-09-05
RU2018130764A (en) 2020-03-04

Similar Documents

Publication Publication Date Title
SG11201811432WA (en) Rna for cancer therapy
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201907056XA (en) Compositions and methods for the treatment of hemoglobinopathies
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201807809XA (en) A transient commensal microorganism for improving gut health
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201806342SA (en) Glucagon and glp-1 co-agonists for the treatment of obesity
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201907196YA (en) Composition and methods for preventing radiation injury and promoting tissue regeneration
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201900845YA (en) Uses of il-13 antagonists for treating atopic dermatitis
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201805001UA (en) Method of treating influenza a
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201901389XA (en) Combination therapy with glutaminase inhibitors
SG11201809882XA (en) Pharmaceutical combinations for treating cancer